A first-of-its-kind AI lab from Lilly and NVIDIA aims to create continuous, data-driven systems that accelerate drug discovery.
NVIDIA and Eli Lilly have announced a first-of-its-kind AI co-innovation lab aimed at rebuilding the drug discovery process from the ground up. The two companies will invest up to $1 billion over five years to bring together advanced AI modeling, large-scale data generation, robotics and automated agentic wet-lab systems.
The lab will operate in the San Francisco Bay Area, where Lilly researchers and NVIDIA AI engineers will work side by side to create continuous learning systems that link real-world experiments with computational models. The goal is to accelerate identification, optimization and validation of potential medicines, with NVIDIA’s BioNeMo platform and next-generation architectures such as Vera Rubin at the core of the effort.
The collaboration builds on Lilly’s existing AI supercomputer and expands opportunities to use AI across clinical development, manufacturing and supply chain reliability. Both companies view this as a blueprint for the next era of drug discovery: rapid experimentation, scalable data generation and AI models custom-built to support scientific decision making.
Why This Matters for Data Analysts
The Lilly–NVIDIA collaboration shows how quickly AI-assisted workflows are becoming central to scientific work. Several themes are directly relevant to analysts who work with automation and model-driven processes:
These developments point to a future where analysts work with AI systems that ingest data, refine models and prepare the next set of actions automatically, while human judgment guides direction and interprets results.
Novo Nordisk has expanded its collaboration with Valo Health, committing $190 million in near-term payments and up to $4.6 billion in potential milestone payments to accelerate the discovery and development of treatments for obesity, type 2 diabetes, and cardiovascular diseases. The expanded agreement, building on their 2023 partnership, increases the number of programs from 11 to 20, increasing their focus on cardiometabolic innovation.
Novo Nordisk leaders have expressed their enthusiasm for the partnership in LinkedIn posts. Marcus Schindler, Novo Nordisk’s Executive Vice President and Chief Scientific Officer, highlighted the strong scientific synergies and high engagement between the teams, emphasizing how leveraging human datasets early in the R&D process is driving scientific excellence. Similarly, Dave Moore, Executive Vice President of US Operations, celebrated the rapid expansion as a testament to the value created by combining Novo Nordisk’s deep understanding of cardiometabolic diseases with Valo’s AI-powered platform.
At the core of the partnership is Valo’s Opal Computational Platform™, a groundbreaking AI-powered system designed to accelerate drug discovery and development by leveraging high-quality human data. Unlike traditional approaches, which are often hindered by fragmented data and inefficiencies, Opal integrates large-scale human-centric datasets with advanced machine learning models. The platform continuously learns and improves by generating and integrating new data during every stage of drug development. It also incorporates proprietary Biowire technology to produce human-relevant tissue in the lab, enabling precise simulations of drug responses before clinical trials. This end-to-end approach minimizes data loss, accelerates insights, and aims to produce more effective treatments that reach patients faster.
This initiative underscores Novo Nordisk's strategic investment in AI and reinforces its commitment to combating chronic diseases. As the two companies expand their partnership, the focus remains on achieving groundbreaking advancements in cardiometabolic treatments.
For more information, please visit Fierce Biotech.
Left to right: Jensen Huang, founder and CEO of NVIDIA | Nadia Carlsten, CEO of DCAI | HM King Frederik X of Denmark
Source: Novo Nordisk Foundation
Denmark has ushered in a new era of artificial intelligence with the launch of its first AI supercomputer, Gefion. This groundbreaking system, developed on the NVIDIA DGX SuperPOD platform, was ceremonially powered on by NVIDIA’s CEO Jensen Huang and King Frederik X of Denmark, marking a pivotal moment in the nation’s technological advancement.
Gefion, which is operated by the Danish Centre for AI Innovation (DCAI), is designed to solve some of the most complex challenges across sectors like biotechnology, quantum computing, and clean energy. Thomas Senderovitz, Senior VP Data Science at Novo Nordisk, wrote in a public LinkedIn post about the event, “Today, the amazing and groundbreaking Gefion supercomputer—the new Danish world-class instrument for generating insights and solving complex problems through artificial intelligence—was turned on by NVIDIA’s CEO and founder Jensen Huang and HM King Frederik. A very special moment to remember for generations to come!”
The supercomputer is part of a larger public-private initiative, funded by the Novo Nordisk Foundation and the Export and Investment Fund of Denmark, and it stands as Denmark’s largest sovereign AI infrastructure. This positions Denmark not only as a leader in AI research and innovation but also enhances the country’s ability to address global challenges, from accelerating drug discovery to improving climate models.
With the Gefion supercomputer, Denmark aims to foster an AI ecosystem that reflects its unique cultural and industrial strengths, while advancing the scientific community's ability to tackle some of the world’s most pressing issues.
For more information about Gefion and DCAI, visit the Danish Centre for AI Innovation.
Page 2 of 2
